Medicenna Therapeutics Corp. (MDNAF)
- Previous Close
1.8300 - Open
1.7600 - Bid --
- Ask --
- Day's Range
1.7500 - 1.8800 - 52 Week Range
0.1510 - 2.1000 - Volume
69,464 - Avg. Volume
139,544 - Market Cap (intraday)
140.584M - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jun 25, 2024 - Jul 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.51
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
www.medicenna.comRecent News: MDNAF
Performance Overview: MDNAF
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDNAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDNAF
Valuation Measures
Market Cap
134.46M
Enterprise Value
118.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.05
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.57%
Return on Equity (ttm)
-59.47%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.42M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
21.76M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.5M
Research Analysis: MDNAF
Company Insights: MDNAF
MDNAF does not have Company Insights